Analysis of the mechanisms modulating EGFR signaling and resistance to EGFR-targeted inhibitors has provided insights into the specific inhibition of EGFR signaling activity, e.g., by TKIs and mAbs, and has permitted further exploration of the development of drug-resistant cancers. The gene discussed is EGFR; the disease is cancer.